TELA Bio (TELA) Asset Writedowns and Impairment (2018 - 2026)

TELA Bio's Asset Writedowns and Impairment history runs 9 years deep, the most recent figure standing at $935000.0 for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 48.41% year-over-year to $935000.0 in Q1 2026; TTM through Mar 2026 was $2.7 million, a 11.9% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 20.14% from the prior year.
• Asset Writedowns and Impairment rose to $935000.0 in Q1 2026 per TELA's latest filing, from $818000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $1.4 million in Q4 2024 and bottomed at $57000.0 in Q4 2022.
• The 5-year median for Asset Writedowns and Impairment is $576000.0 (2023), against an average of $560588.2.
• Biggest YoY gain for Asset Writedowns and Impairment was 640.35% in 2023; the steepest drop was 63.22% in 2023.
• Year by year, Asset Writedowns and Impairment stood at $57000.0 in 2022, then surged by 640.35% to $422000.0 in 2023, then surged by 229.86% to $1.4 million in 2024, then sank by 41.24% to $818000.0 in 2025, then rose by 14.3% to $935000.0 in 2026.
• Per Business Quant, the three latest TELA Asset Writedowns and Impairment figures stand at $935000.0 (Q1 2026), $818000.0 (Q4 2025), and $632000.0 (Q3 2025).